Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

UNAUDITED FINANCIAL RESULTS OF CR PHARMACEUTICAL HOLDINGS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2026 IN RELATION TO ISSUANCE OF MEDIUM TERM NOTES IN THE PRC

Reference is made to: (i) the announcement dated 29 May 2026 in relation to, among others, the proposed issuance of medium term notes in the PRC by China Resources Pharmaceutical Holdings Company Limited (華潤醫藥控股有限公司) ("**CR Pharmaceutical Holdings**"), a wholly owned subsidiary of the Company; (ii) the announcement dated 22 July 2026 in relation to, among others, the completion of the issuance of the first tranche of medium term notes for the year of 2026 in the PRC by CR Pharmaceutical Holdings; (iii) the announcement dated 29 July 2026 in relation to, among others, the completion of the issuance of the second tranche of medium term notes for the year of 2026 in the PRC by CR Pharmaceutical Holdings; and (iv) the announcement dated 23 October 2026 in relation to, among others, the completion of the issuance of the third tranche of medium term notes for the year of 2026 in the PRC by CR Pharmaceutical Holdings (the "**Announcements**"). Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless stated otherwise herein.

In accordance with the relevant rules and regulations in the PRC and in connection with its issuance of medium term notes in the PRC, CR Pharmaceutical Holdings has published its unaudited financial statements for the nine months ended 30 September 2026 on the websites of China Money and Shanghai Clearing House in connection with the medium term notes.

The unaudited financial statements of CR Pharmaceutical Holdings for the nine months ended 30 September 2026 (the "**Unaudited Financial Statements of CR Pharmaceutical Holdings**") are enclosed to this announcement for the Company's shareholders' information only. The Unaudited Financial Statements of CR Pharmaceutical Holdings were prepared in Chinese and have been translated for publication in English and Chinese. In the event of any inconsistency between the two versions, the Chinese version shall prevail. In addition,

the Unaudited Financial Statements of CR Pharmaceutical Holdings have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company's auditors, and may require adjustments during the course of auditing. Such financial information is limited to CR Pharmaceutical Holdings only and does not represent or provide a complete view of the operational or financial status of the Group.

Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 28 October 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mdm. Zhang Jing and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
CONSOLIDATED BALANCE SHEET
SEPTEMBER 2026

Unit: RMB

Item	Closing balance	Opening Balance	Item	Closing balance	Opening Balance
Current assets:			**Current liabilities:**		
Monetary fund	20,046,173,604.13	24,173,133,594.20	Short-term borrowings	43,087,842,935.52	40,737,794,364.47
Held-for-trading financial assets	12,497,872,769.52	12,069,041,094.95	Held-for-trading financial liabilities	–	–
Derivative financial assets	–	–	Notes payable and accounts payable	70,684,800,680.36	64,745,270,978.14
Notes receivable	463,395,197.21	586,483,121.19	Including: Notes payable	20,955,298,244.02	21,745,649,407.90
Accounts receivable	103,224,320,319.79	92,595,722,664.81	Accounts payable	49,729,502,436.34	42,999,621,570.24
Financing receivables	14,393,909,175.56	13,178,431,543.53	Receipts in advance	165,964,207.54	93,937,978.20
Prepayment	4,960,195,938.13	4,016,056,359.42	Contract liabilities	4,634,444,347.96	4,182,764,833.36
Other receivables	9,385,788,705.72	8,622,449,150.11	Staff remuneration payable	3,731,147,325.40	4,211,743,649.25
Including: Interest receivable	200,187.55	836,001.52	Including: Wages payable	895,226,846.26	1,080,675,958.90
Dividends receivable			Benefits payable	–	–
Inventory	47,361,615,536.14	43,276,039,279.45	Taxation payable	1,495,389,599.74	2,015,479,566.00
Including: Raw materials	3,814,374,255.14	3,202,249,965.23	Including: Tax payable	1,364,119,749.54	1,868,335,230.98
Goods in stock (finished products)	39,581,711,107.42	35,292,622,462.01	Other payables	23,298,254,868.72	21,431,783,225.55
Contract assets	38,281,752.74	55,493,546.50	Including: Interest payable	8,557,278.42	7,674,319.44
Assets held for sale	35,325,622.46	37,996,383.69	Dividends payable	7,611,856,391.15	4,732,832,203.56
Non-current assets due within one year	2,892,712,742.98	3,235,028,566.39	Insurance contract liabilities	–	–
Other current assets	2,093,370,941.45	2,301,374,310.71	Liabilities held for sale	–	–
			Non-current liabilities due within one year	5,844,310,022.35	8,110,938,853.35
			Other current liabilities	464,491,671.26	640,430,558.82
Total current assets	**217,392,962,305.82**	**204,147,249,614.95**	**Total current liabilities**	**153,406,645,658.85**	**146,170,144,007.14**
Non-current assets:			**Non-current liabilities:**		
Other debt investments			Long-term borrowings	7,253,957,834.33	11,149,853,384.60
Debt investments	83,280,094.96	79,280,094.96	Bonds payable	18,750,663,283.66	10,196,868,303.42
Long-term receivables	727,823,672.63	831,459,823.02	Long-term payables	404,335,926.29	408,549,258.29
Other equity instruments investments	10,942,625.57	10,942,625.57	Including: Long-term payables	160,785,920.00	160,785,920.00
Long-term equity investments	6,143,060,334.52	6,041,161,311.87	Special payables	243,550,006.29	247,763,338.29
Investment properties	368,007,969.06	353,339,799.28	Long-term employee remuneration payable	771,703,715.32	744,513,538.04
Other non-current financial assets	613,212,129.92	833,242,321.57	△Deferred revenue	812,309,270.55	781,520,816.97
Fixed assets	22,172,495,858.83	22,712,024,741.91	Estimated liabilities	1,369,421.26	1,321,000.65
Including: Disposal of fixed assets	15,205,825.57	9,711,113.40	Deferred income tax liabilities	1,967,767,155.03	1,892,214,582.04
Right-of-use assets	1,142,525,680.89	1,279,364,857.34	Lease liabilities	665,791,541.93	730,025,422.66
Construction in progress	3,097,796,841.63	2,587,796,563.58	Other non-current liabilities	3,814,940.00	3,814,940.00
Including: Construction materials	176,532.79	168,450.73	Including: Special reserve		
Biological assets for production	24,542,263.59	20,585,150.19	**Total non-current liabilities**	**30,631,713,088.37**	**25,908,681,246.67**
Oil and gas assets	–	–	**Total liabilities**	**184,038,358,747.22**	**172,078,825,253.81**

Item	Closing balance	Opening Balance	Item	Closing balance	Opening Balance
Intangible assets	13,231,296,396.48	13,309,319,592.85	**Owners' equity (or shareholders' equity):**		
Including: Land use right	5,100,216,042.90	4,882,090,433.67	Paid-in capital (equity)	21,807,000,000.00	21,007,000,000.00
Development expenses	2,880,008,586.01	2,960,721,894.91	State-owned capital		
Goodwill	24,354,411,140.36	24,342,133,911.47	Collective capital		
Long-term deferred expenses	470,079,603.04	473,179,715.38	Legal person capital		
Deferred income tax assets	2,702,603,234.08	2,347,164,484.40	Including: State-owned legal person capital		
Other non-current assets	3,710,686,988.72	3,974,805,304.11	Collectively-owned legal person capital		
Including: Contract assets	1,611,257.60	2,342,483.75	Individual's capital		
			Foreign capital		
			Capital surplus	189,760,122.09	165,697,373.12
			Less: Treasury shares		
			Other comprehensive income	30,412,648.23	46,898,136.52
			Including: Differences on translation of foreign currency	15,405,905.04	25,606,055.86
			Surplus reserves	972,696,791.37	972,961,454.68
Total non-current assets	**81,732,773,420.28**	**82,156,522,192.41**	Special reserves	4,814,444.04	5,027,989.57
			Undistributed profits	19,764,136,068.16	18,176,543,251.84
			Total equity attributable to owners of the parent company	**42,768,820,073.89**	**40,374,128,205.73**
			△Minority interests	72,318,556,904.99	73,850,818,347.82
			Total owners' equity	**115,087,376,978.88**	**114,224,946,553.55**
Total assets	**299,125,735,726.10**	**286,303,771,807.36**	**Total liabilities and owners' equity**	**299,125,735,726.10**	**286,303,771,807.36**

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
CONSOLIDATED STATEMENT OF PROFIT OR LOSS
JANUARY TO SEPTEMBER 2026

Unit: RMB

Item	In the month	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
I. Operating revenue	**28,729,351,744.87**	**203,527,555,850.92**	**200,881,213,746.26**
Including: Revenue from principal businesses	28,538,406,096.71	202,190,151,584.73	199,401,323,056.70
Revenue from other businesses	190,945,648.16	1,337,404,266.18	1,479,890,689.56
II. Operating costs	**22,958,614,212.84**	**170,566,471,309.05**	**167,321,576,385.23**
Including: Costs for principal businesses	22,900,771,680.39	170,008,728,887.44	166,539,409,396.17
Costs for other businesses	57,842,532.45	557,742,421.61	782,166,989.06
Tax and surcharge	151,612,632.72	868,423,304.85	848,995,447.57
Selling expenses	2,506,767,255.20	15,070,756,594.47	15,535,775,705.75
Management expenses	656,690,659.71	5,027,356,115.23	4,838,636,510.73
Including: Entertainment expenses	4,906,341.09	32,987,235.62	35,779,742.49
Research and development expenses	187,419,461.39	1,693,081,067.96	1,630,214,040.34
Finance costs	126,277,682.26	1,167,825,995.17	1,241,179,892.38
Including: Interest expenses	141,530,121.82	1,249,944,869.20	1,452,284,116.66
Interest income	31,342,581.07	206,102,644.49	285,998,192.47
Net loss from exchange (net gain is represented by "–")	7,849,684.39	53,483,619.19	9,452,749.09
Other revenue	43,020,935.96	324,423,886.17	472,551,277.80
Gain from investment (loss is represented by "–")	(11,483,870.39)	244,130,185.93	152,286,858.14
Including: Gains from investment in associates and joint ventures	24,959,657.83	248,649,063.68	175,193,245.49
Net gains from hedging exposure (loss is represented by "–")	–	–	–
Add: Gains from changes in fair values (loss is represented by "–")	(27,032,581.26)	(24,755,392.45)	170,512,193.65
Impairment losses of assets	288,963,782.11	445,823,922.40	249,986,163.21
Loss on credit impairment	121,132,789.09	918,329,093.17	792,472,459.16
Gains from disposal of assets	145,069,933.29	209,641,531.77	67,559,358.88

Item	In the month	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
III. Operating profits (loss is represented by "–")	**1,881,447,687.16**	**8,522,928,660.05**	**9,285,286,830.38**
Add: Non-operating income	18,203,890.67	193,854,007.97	160,881,268.50
Including: Gains from exchanging non-monetary assets	–	–	–
Government subsidies	–	–	15,019.20
Less: Non-operating expenses	15,389,193.95	89,982,448.07	91,156,671.47
Including: Loss on exchanging non-monetary assets	–	–	–
IV. Total profits (total loss is represented by "–")	**1,884,262,383.88**	**8,626,800,219.95**	**9,355,011,427.41**
Less: Income tax expenses	276,360,770.23	1,654,578,469.94	1,792,192,634.58
V. Net profits (net loss is represented by "–")	**1,607,901,613.65**	**6,972,221,750.01**	**7,562,818,792.82**
Including: Net profits of the absorbed party before business combination under common control			
Net profits attributable to the owners of the parent company	441,857,916.71	2,390,575,265.00	2,562,946,606.80
*Gains and losses of minority interests	1,155,147,863.61	4,483,583,985.01	4,951,084,686.02
Profit attributable to holders of perpetual capital instruments	10,895,833.33	98,062,500.00	48,787,500.00
VI. Other comprehensive income, net of tax	**(8,384,945.89)**	**(97,375,605.58)**	**13,625,461.58**
(I) Other comprehensive income that cannot be reclassified into profit or loss	(18,390.35)	(51,057,213.28)	20,629,957.07
Changes arising from remeasurement of defined benefit plan	–	2,704.45	–
Other comprehensive income that cannot be reclassified into profit or loss under the equity method	(18,390.35)	(51,059,917.73)	23,848,864.96
Changes in fair value of other equity instrument investments	–	–	(3,218,907.89)
(II) Other comprehensive income that may be reclassified to profit or loss	(8,366,555.54)	(46,318,392.29)	(7,004,495.49)
Other comprehensive income that may be reclassified to profit or loss under equity method	–	(79,155.96)	119,877.55
Changes in fair value of other debt investments	–	264.35	(12,986.68)
Amount included in other comprehensive income on reclassification of financial assets	–	–	–

Item		In the month	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
	Provision for credit impairment of other debt investment	–	–	–
	Revaluation of fixed assets	–	–	–
	Cash flows hedging reserve	–	–	–
	Differences arising from translation of foreign currency	(8,366,555.54)	(46,236,796.23)	(7,111,386.36)
	Others	–	(2,704.45)	–
VII.	**Total comprehensive income**	**1,599,516,370.10**	**6,874,846,144.43**	**7,576,444,254.41**
VIII.	**Earnings per share:**	**–**	**–**	**–**
	Basic earnings per share	–	–	–
	Diluted earnings per share	–	–	–
	Add: Undistributed profit at the beginning of the year		18,174,155,591.48	14,907,525,621.28
	Changes in accounting policies		–	–
	Losses covered by surplus reserve		–	–
	Other adjustment factors		–	–
IX.	**Distributable profit**		**20,564,730,856.48**	**17,470,472,228.09**
	Less: Appropriation of statutory surplus reserve		–	(0.01)
	Appropriation for staff bonuses and benefit funds		–	–
	Appropriation for reserve funds		–	–
	Appropriation for company development funds		–	–
	Others		–	–
X.	**Distributable profit attributable to investors**		**20,564,730,856.49**	**17,470,472,228.08**
	Preference shares dividends payable			
	Appropriation of discretionary surplus reserve		–	–
	Ordinary shares dividends payable		(800,000,000.00)	10,992.51
	Ordinary shares dividends converted to equity		–	–
	Others		(594,788.33)	594,788.33
XI.	**Undistributed profit**	**–**	**19,764,136,068.16**	**17,471,078,008.91**

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
CONSOLIDATED STATEMENT OF CASH FLOWS
JANUARY TO SEPTEMBER 2026

Unit: RMB

Item	In the month	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
I. Cash flows from operating activities:			
Cash received from the sales of goods and the rendering of services	26,810,739,832.14	209,519,967,191.45	205,239,230,137.69
Refund of taxes and levies	7,377,560.65	81,114,051.78	63,262,284.74
Cash received relating to other operating activities	1,459,729,818.39	10,852,694,456.42	10,867,390,169.40
Sub-total of cash inflows from operating activities	**28,277,847,211.18**	**220,453,775,699.66**	**216,169,882,591.83**
Cash paid for goods purchased and services received	21,513,541,579.05	172,880,116,370.53	168,461,828,232.10
Cash paid to and for employees	1,146,609,053.49	12,083,878,344.33	11,488,477,554.65
Payments of all types of taxes	479,669,562.66	7,756,555,167.89	7,639,767,500.70
Cash payments relating to other operating activities	2,600,042,361.57	22,880,837,260.23	22,509,756,583.06
Sub-total of cash outflows from operating activities	**25,739,862,556.78**	**215,601,387,142.98**	**210,099,829,870.51**
Net cash flow from operating activities	**2,537,984,654.40**	**4,852,388,556.67**	**6,070,052,721.31**
II. Cash Flow From Investing Activities:			
Cash received from investment recovery	4,650,672,856.22	41,451,017,770.35	26,994,520,534.51
Cash received from returns on investments	45,044,262.97	539,352,236.13	397,054,468.16
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	32,754,681.58	494,460,862.08	66,895,354.35
Net cash received from disposals of subsidiaries and other operating units	–	–	179,709,625.93
Cash received relating to other investing activities	353,916.67	32,664,482.73	353,802,280.44
Sub-total of cash inflows from investing activities	**4,728,825,717.44**	**42,517,495,351.29**	**27,991,982,263.39**
Cash paid to acquire fixed assets, intangible assets and other long-term assets	299,914,634.54	2,545,654,504.19	2,304,591,025.20
Cash paid for investments	5,445,826,899.20	39,674,951,966.87	27,555,934,349.40
Net cash paid for acquisition of subsidiaries and other operational units	65,486,194.59	109,979,677.00	5,262,786,993.69
Cash payments relating to other investing activities	4,001,320.31	1,814,964,321.38	21,799,790.67
Sub-total of cash outflows from investing activities	**5,815,229,048.64**	**44,145,550,469.44**	**35,145,112,158.96**
Net cash flow from investing activities	**(1,086,403,331.20)**	**(1,628,055,118.14)**	**(7,153,129,895.57)**

III. Cash flow from financing activities:			
Cash received from capital contribution	–	45,492,000.00	119,493,600.00
Including: Cash received by subsidiaries from investments of minority shareholders			
Cash received from borrowings	5,027,016,934.25	44,588,767,186.47	51,523,765,116.87
Cash received from issuance of bonds	304,905.66	7,699,160,377.36	5,000,000,000.00
Cash payments relating to other financing activities	(29,863,541.72)	3,001,302,336.35	3,774,360,945.05
Sub-total of cash inflows from financing activities	4,997,458,298.19	55,334,721,900.18	60,417,619,661.92
Cash payments for debts settlement	4,785,102,944.22	54,177,263,859.23	53,199,703,158.96
Cash payments for distribution of dividends, profits, or interest expenses	548,306,291.46	4,238,174,131.77	3,798,315,310.93
Including: Dividends and profits paid by subsidiaries to minority shareholders	4,980,844.43	231,978,037.63	188,529,577.34
Cash payments relating to other financing activities	485,908,495.95	3,864,682,592.16	5,272,287,591.16
Sub-total of cash outflows from financing activities	**5,819,317,731.63**	**62,280,120,583.16**	**62,270,306,061.05**
Net cash flow from financing activities	**(821,859,433.44)**	**(6,945,398,682.98)**	**(1,852,686,399.13)**
IV. Effect of foreign exchange rate changes on cash and cash equivalents	(12,529,568.85)	(46,300,090.77)	(2,875,449.73)
V. Net increase in cash and cash equivalents	**617,192,320.91**	**(3,767,365,335.22)**	**(2,938,639,023.11)**
Add: Opening balance of cash and cash equivalent	11,380,683,545.36	15,765,241,201.49	16,323,311,787.22
VI. Closing balance of cash and cash equivalents	**11,997,875,866.27**	**11,997,875,866.27**	**13,384,672,764.11**

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
BALANCE SHEET
SEPTEMBER 2026

Unit: RMB

Item	Closing balance	Opening Balance	Item	Closing balance	Opening Balance
Current assets:			**Current liabilities:**		
Monetary fund	823,601,042.89	605,327,754.56	Short-term borrowings	5,257,777.77	1,501,386,666.66
Held-for-trading financial assets	2,208,177,921.60	1,605,145,283.04	Held-for-trading financial liabilities	–	–
Derivative financial assets	–	–	Notes payable and accounts payable	–	–
Notes receivable	–	–	Including: Notes payable	–	–
Accounts receivable	–	–	Accounts payable	–	–
Financing receivables	–	–	Receipts in advance	–	–
Prepayment	562,334.23	190,584.60	Contract liabilities	–	–
Other receivables	14,173,095,691.48	12,231,194,371.37	Staff remuneration payable	44,840,062.93	65,267,041.33
Including: Interest receivable	–	–	Including: Wages payable	–	–
Dividends receivable	9,304,387,661.11	6,572,748,449.32	Benefits payable	–	–
Inventory	–	–	Taxation payable	7,226,227.34	7,768,096.09
Including: Raw materials	–	–	Including: Tax payable	7,226,227.34	7,768,096.09
Goods in stock (finished products)	–	–	Other payables	669,256,319.64	1,151,408,704.22
Contract assets	–	–	Including: Interest payable	–	–
Assets held for sale	–	–	Dividends payable	–	–
Non-current assets due within one year	–	–	Insurance contract liabilities	–	–
Other current assets	3,012,533.82	2,379,335.64	Liabilities held for sale	–	–
			Non-current liabilities due within one year	22,768,570.24	2,312,950,189.86
			Other current liabilities	–	–
Total current assets	**17,208,449,524.02**	**14,444,237,329.21**	**Total current liabilities**	**749,348,957.92**	**5,038,780,698.16**
Non-current assets:			**Non-current liabilities:**		
Other debt investments	–	–	Long-term borrowings	194,688,618.67	222,082,502.61
Debt investments	–	–	Bonds payable	5,752,383,930.55	2,200,000,000.00
Long-term receivables	–	–	Long-term payables	–	–
Other equity instruments investments	–	–	Including: Long-term payables	–	–
Long-term equity investments	16,779,254,181.89	16,698,998,641.73	Special payables	–	–
Investment properties	–	–	Long-term employee remuneration payable	243,290,000.00	232,660,000.00
Other non-current financial assets	–	–	△Deferred revenue	–	–
Fixed assets	2,710,560.11	2,545,046.50	Estimated liabilities	–	–
Including: Disposal of fixed assets	–	–	Deferred income tax liabilities	–	–
Right-of-use assets	22,105,530.89	27,206,807.21	Lease liabilities	–	21,133,725.58
Construction in progress	–	260,030.96	Other non-current liabilities	–	–
Including: Construction materials	–	–	Including: Special reserve		
Biological assets for production	–	–	**Total non-current liabilities**	**6,190,362,549.22**	**2,675,876,228.19**
Oil and gas assets	–	–	**Total liabilities**	**6,939,711,507.14**	**7,714,656,926.35**

Item	Closing balance	Opening Balance	Item	Closing balance	Opening Balance
Intangible assets	–	–	**Owners' equity (or shareholders' equity):**		
Including: Land use right	–	–	Paid-in capital (equity)	21,807,000,000.00	21,007,000,000.00
Development expenses	–	–	State-owned capital		
Goodwill	–	–	Collective capital		
Long-term deferred expenses	–	–	Legal person capital		
Deferred income tax assets	487,111.47	487,111.47	Including: State-owned legal person capital		
Other non-current assets	–	–	Collectively- owned legal person capital		
Including: Contract assets	–	–	Individual's capital		
			Foreign capital		
			Capital surplus	13,253,773.51	13,253,773.51
			Less: Treasury shares	–	–
			Other comprehensive income	74,610,416.58	74,610,416.58
			Including: Differences on translation of foreign currency	–	–
			Surplus reserves	1,213,171,274.84	1,213,171,274.84
Total non-current assets	**16,804,557,384.36**	**16,729,497,637.87**	Special reserves	–	–
			Undistributed profits	3,965,259,936.30	1,151,042,575.80
			Total equity attributable to owners of the parent company	**27,073,295,401.23**	**23,459,078,040.73**
			△Minority interests	–	–
			Total owners' equity	**27,073,295,401.23**	**23,459,078,040.73**
Total assets	**34,013,006,908.38**	**31,173,734,967.08**	**Total liabilities and owners' equity**	**34,013,006,908.38**	**31,173,734,967.08**

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
STATEMENT OF PROFIT OR LOSS
JANUARY TO SEPTEMBER 2026

Unit: RMB

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
I. Operating revenue	**471,698.11**	**471,698.11**
Including: Revenue from principal businesses	–	–
Revenue from other businesses	471,698.11	471,698.11
II. Operating costs	**–**	**–**
Including: Costs for principal businesses	–	–
Costs for other businesses	–	–
Tax and surcharge	753,754.42	550,552.00
Selling expenses	–	–
Management expenses	139,993,501.32	109,269,054.26
Including: Entertainment expenses	30,345.20	62,949.30
Research and development expenses	–	–
Finance costs	86,396,434.50	133,747,607.93
Including: Interest expenses	87,941,643.07	147,333,625.94
Interest income	1,872,402.15	14,748,706.60
Net Loss from exchange (net gain is represented by "–")	(2,330,752.26)	(679,080.44)
Other revenue	–	166,065.61
Gain from investment (loss is represented by "–")	3,752,612,528.44	908,346,956.77
Including: Gains from investment in associates and joint ventures	80,255,540.16	87,937,573.83
Net gains from hedging exposure (loss is represented by "–")	–	–
Add: gains from changes in fair values (loss is represented by "–")	26,298,533.09	27,644,145.69
Impairment losses of assets	–	–
Loss on credit impairment	–	32,069,477.09
Gains from disposal of assets	(3,315.23)	(5,500.00)

Item		Accumulated amount for the year	Accumulated amount for the corresponding period of last year
III.	**Operating profits (loss is represented by "–")**	**3,552,235,754.17**	**660,986,674.90**
	Add: Non-operating income	62,890,606.34	30,749,979.90
	Including: Gains from exchanging non-monetary assets	–	–
	Government subsidies	–	–
	Less: Non-operating expenses	909,000.00	3,124,424.23
	Including: Loss on exchanging non-monetary assets	–	–
IV.	**Total profits (total loss is represented by "–")**	**3,614,217,360.51**	**688,612,230.57**
	Less: Income tax expenses	–	(668,644.86)
V.	**Net profits (net loss is represented by "–")**	**3,614,217,360.51**	**689,280,875.43**
	Including: Net gains of the absorbed party before business combination under common control		
	Net profits attributable to the owners of the parent company	3,614,217,360.51	689,280,875.43
	*Gains and losses of minority interests	–	–
	Profit attributable to holders of perpetual capital instruments	–	–
VI. Other comprehensive income, net of tax		**–**	**–**
	(I) Other comprehensive income that cannot be reclassified into profit and loss	–	–
	Changes arising from remeasurement of defined benefit plan	–	–
	Other comprehensive income that cannot be reclassified into profit or loss under the equity method	–	–
	Changes in fair value of other equity instrument investments	–	–
	(II) Other comprehensive income that may be reclassified to profit or loss	–	–
	Other comprehensive income that may be reclassified to profit or loss under equity method	–	–
	Change in fair value of other debt investments	–	–
	Amount included in other comprehensive income on reclassification of financial assets	–	–
	Provision for credit impairment of other debt investment	–	–
	Revaluation of fixed assets	–	–
	Cash flows hedging reserve	–	–
	Exchange differences arising from translation of foreign currency	–	–
	Others	–	–

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
VII. Total comprehensive income	**3,614,217,360.51**	**689,280,875.43**
VIII. Earnings per share:	**–**	**–**
Basic earnings per share	–	–
Diluted earnings per share	–	–
Add: undistributed profit at the beginning of the year	1,151,042,575.80	174,815,165.99
Changes in accounting policies	–	–
Losses covered by surplus reserve	–	–
Other adjustment factors	–	–
IX. Distributable profit	**4,765,259,936.30**	**864,096,041.42**
Less: Appropriation of statutory surplus reserve	–	–
Appropriation for staff bonuses and benefit funds	–	–
Appropriation for reserve funds	–	–
Appropriation for company development funds	–	–
Others	–	–
X. Distributable profit attributable to investors	4,765,259,936.30	864,096,041.42
Preference shares dividends payable		
Appropriation of discretionary surplus reserve	–	–
Ordinary shares dividends payable	(800,000,000.00)	–
Ordinary shares dividends converted to equity	–	–
Others	–	–
XI. Undistributed profit	3,965,259,936.30	864,096,041.42

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
STATEMENT OF CASH FLOWS
JANUARY TO SEPTEMBER 2026

Unit: RMB

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
I. Cash flow from operating activities:		
Cash received from the sales of goods and the rendering of services	514,910.54	504,239.60
Refund of taxes and levies	–	–
Cash received relating to other operating activities	1,602,285,238.73	750,665,264.20
Sub-total of cash inflows from operating activities	**1,602,800,149.27**	**751,169,503.80**
Cash paid for goods purchased and services received	1,088,525.78	296,483.86
Cash paid to and for employees	123,008,277.27	116,195,324.02
Payments of all types of taxes	1,554,345.14	1,301,921.76
Cash payments relating to other operating activities	1,084,739,470.81	875,057,826.03
Sub-total of cash outflows from operating activities	**1,210,390,619.00**	**992,851,555.67**
Net cash flow from operating activities	**392,409,530.27**	**(241,682,051.87)**
II. Cash flow from investing activities:		
Cash received from investment recovery	5,033,265,894.53	4,582,996,149.00
Cash received from returns on investments	940,717,776.49	419,282,310.60
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	–	–
Net cash received from disposals of subsidiaries and other operating units	–	–
Cash received relating to other investing activities	–	802.28
Sub-total of cash inflows from investing activities	5,973,983,671.02	5,002,279,261.88
Cash paid to acquire fixed assets, intangible assets and other long-term assets	296,491.90	621,450.44
Cash paid for investments	5,740,000,000.00	3,480,000,000.00
Net cash paid for acquisition of subsidiaries and other operating units	–	371,636,801.95
Cash payments relating to other investing activities	–	–
Sub-total of cash outflows from investing activities	**5,740,296,491.90**	**3,852,258,252.39**
Net cash flow from investing activities	**233,687,179.12**	**1,150,021,009.49**

III. Cash flow from financing activities:		
Cash received from capital contribution	–	–
Including: Cash received by subsidiaries from investments of minority shareholders		
Cash received from borrowings	–	87,000,000.00
Cash received from issuance of bonds	1,499,160,377.36	–
Cash received relating to other financing activities	1,435,527,810.30	1,606,281,873.21
Sub-total of cash inflows from financing activities	**2,934,688,187.66**	**1,693,281,873.21**
Cash payments for debts settlement	1,821,866,667.00	2,001,458,347.81
Cash payments for distribution of dividends, profits, or interest expenses	40,765,453.08	182,987,873.85
Including: Dividends and profits paid by subsidiaries to minority shareholders	–	–
Cash payments relating to other financing activities	1,549,879,397.62	813,622,904.77
Sub-total of cash outflows from financing activities	**3,412,511,517.70**	**2,998,069,126.43**
Net cash flow from financing activities	**(477,823,330.04)**	**(1,304,787,253.22)**
IV. Effect of foreign exchange rate changes on cash and cash equivalents	(91.02)	(26.54)
V. Net increase in cash and cash equivalents	**148,273,288.33**	**(396,448,322.14)**
Add: Opening balance of cash and cash equivalents	575,327,754.56	540,934,149.52
VI. Closing balance of cash and cash equivalents	**723,601,042.89**	**144,485,827.38**